Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 0.03 [0, 0.42]
1 study · 35 participants
Low

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 0.03 [0, 0.41]
1 study · 45 participants
Low

Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 1 [0.91, 1.1]
1 study · 44 participants
Low